Your browser doesn't support javascript.
loading
Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer.
Langille, Ellen; Al-Zahrani, Khalid N; Ma, Zhibo; Liang, Minggao; Uuskula-Reimand, Liis; Espin, Roderic; Teng, Katie; Malik, Ahmad; Bergholtz, Helga; Ghamrasni, Samah El; Afiuni-Zadeh, Somaieh; Tsai, Ricky; Alvi, Sana; Elia, Andrew; Lü, YiQing; Oh, Robin H; Kozma, Katelyn J; Trcka, Daniel; Narimatsu, Masahiro; Liu, Jeff C; Nguyen, Thomas; Barutcu, Seda; Loganathan, Sampath K; Bremner, Rod; Bader, Gary D; Egan, Sean E; Cescon, David W; Sørlie, Therese; Wrana, Jeffrey L; Jackson, Hartland W; Wilson, Michael D; Witkiewicz, Agnieszka K; Knudsen, Erik S; Pujana, Miguel Angel; Wahl, Geoffrey M; Schramek, Daniel.
Afiliação
  • Langille E; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Al-Zahrani KN; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Ma Z; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Liang M; Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, California.
  • Uuskula-Reimand L; Hospital for Sick Children, Toronto, Ontario, Canada.
  • Espin R; Hospital for Sick Children, Toronto, Ontario, Canada.
  • Teng K; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
  • Malik A; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Bergholtz H; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Ghamrasni SE; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Afiuni-Zadeh S; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Tsai R; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Alvi S; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Elia A; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Lü Y; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Oh RH; Hospital for Sick Children, Toronto, Ontario, Canada.
  • Kozma KJ; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Trcka D; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Narimatsu M; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Liu JC; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Nguyen T; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Barutcu S; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Loganathan SK; Hospital for Sick Children, Toronto, Ontario, Canada.
  • Bremner R; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Bader GD; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Egan SE; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Cescon DW; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Sørlie T; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Wrana JL; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Jackson HW; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Wilson MD; Centre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Witkiewicz AK; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Knudsen ES; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Pujana MA; Hospital for Sick Children, Toronto, Ontario, Canada.
  • Wahl GM; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Schramek D; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Cancer Discov ; 12(12): 2930-2953, 2022 12 02.
Article em En | MEDLINE | ID: mdl-36108220
ABSTRACT
Systematically investigating the scores of genes mutated in cancer and discerning disease drivers from inconsequential bystanders is a prerequisite for precision medicine but remains challenging. Here, we developed a somatic CRISPR/Cas9 mutagenesis screen to study 215 recurrent "long-tail" breast cancer genes, which revealed epigenetic regulation as a major tumor-suppressive mechanism. We report that components of the BAP1 and COMPASS-like complexes, including KMT2C/D, KDM6A, BAP1, and ASXL1/2 ("EpiDrivers"), cooperate with PIK3CAH1047R to transform mouse and human breast epithelial cells. Mechanistically, we find that activation of PIK3CAH1047R and concomitant EpiDriver loss triggered an alveolar-like lineage conversion of basal mammary epithelial cells and accelerated formation of luminal-like tumors, suggesting a basal origin for luminal tumors. EpiDriver mutations are found in ∼39% of human breast cancers, and ∼50% of ductal carcinoma in situ express casein, suggesting that lineage infidelity and alveogenic mimicry may significantly contribute to early steps of breast cancer etiology.

SIGNIFICANCE:

Infrequently mutated genes comprise most of the mutational burden in breast tumors but are poorly understood. In vivo CRISPR screening identified functional tumor suppressors that converged on epigenetic regulation. Loss of epigenetic regulators accelerated tumorigenesis and revealed lineage infidelity and aberrant expression of alveogenesis genes as potential early events in tumorigenesis. This article is highlighted in the In This Issue feature, p. 2711.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Idioma: En Ano de publicação: 2022 Tipo de documento: Article